Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
NCT07489651 is registered in ClinicalTrials.gov with Reunion Neuroscience Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
- Lead sponsor
- Reunion Neuroscience Inc
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 20, 2026
- Completion date
- September 30, 2027
- Enrollment
- 160 (estimated)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.